What is the 13F Pro Quality Score for CGTX?

13F Pro ranks COGNITION THERAPEUTICS INC (CGTX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CGTX's current score at https://13fpro.ai/research/CGTX (free sign-up required for the full ranking).

Where does 13F Pro source CGTX data?

All COGNITION THERAPEUTICS INC fundamentals and ownership data come directly from SEC EDGAR. COGNITION THERAPEUTICS INC files with the SEC under CIK 1455365. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CGTX in?

COGNITION THERAPEUTICS INC (CGTX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CGTX research updated on 13F Pro?

CGTX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

COGNITION THERAPEUTICS INC(CGTX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1455365 CGTX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

CGTX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for COGNITION THERAPEUTICS INC (CGTX), a Healthcare sector company. CGTX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), COGNITION THERAPEUTICS INC reports net income of $-4.6M, free cash flow of $-5.5M. Top institutional holders of CGTX by reported 13-F value include BIOS Capital Management,, VANGUARD CAPITAL MANAGEMENT, DAVENPORT & Co, based on the most recent SEC filings. CGTX trades on the Nasdaq exchange and files with the SEC under CIK 1455365. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CGTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for COGNITION THERAPEUTICS INC directly from SEC EDGAR.

Net Income

Q1 2026

$-4.6M

Free Cash Flow

Q1 2026

$-5.5M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+30.9% YoY

$-23.5MFY 2025

FY22 $-21.4MFY23 $-25.8MFY24 $-34.0MFY25 $-23.5M

Operating Income

+11.4% YoY

$-47.8MFY 2025

FY22 $-43.6MFY23 $-50.7MFY24 $-54.0MFY25 $-47.8M

EPS (Diluted)

+62.8% YoY

$-0.32FY 2025

FY22 $-0.91FY23 $-0.86FY24 $-0.86FY25 $-0.32

Total Assets

+60.1% YoY

$48.4MFY 2025

FY22 $50.4MFY23 $35.2MFY24 $30.2MFY25 $48.4M

Op. Cash Flow

+13.6% YoY

$-24.6MFY 2025

FY22 $-18.5MFY23 $-16.0MFY24 $-28.5MFY25 $-24.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Income	$-23.5M +30.9%	$-34.0M -31.7%	$-25.8M -20.5%	$-21.4M -82.6%	$-11.7M -49.5%	$-7.8M
Operating Income	$-47.8M +11.4%	$-54.0M -6.4%	$-50.7M -16.5%	$-43.6M -52.3%	$-28.6M -64.3%	$-17.4M
EPS (Diluted)	$-0.32 +62.8%	$-0.86 +0.0%	$-0.86 +5.5%	$-0.91 +70.9%	$-3.13 +57.4%	$-7.35
Total Assets	$48.4M +60.1%	$30.2M -14.0%	$35.2M -30.3%	$50.4M -14.7%	$59.1M +730.7%	$7.1M
Operating Cash Flow	$-24.6M +13.6%	$-28.5M -77.8%	$-16.0M +13.6%	$-18.5M -410.4%	$-3.6M -5.8%	$-3.4M

AI Insight: CGTX Financial Trends

Equity recovered sharply in Q3 2025 to $37M but has since eroded to $30M, while losses persist with no revenue in sight.

• Equity collapsed from $23M in Q2 2024 to $7M in Q2 2025, then spiked to $37M in Q3 2025, likely reflecting a capital raise.

• Net loss narrowed from -$10M in Q3 2024 to -$3M in Q4 2025, but widened again to -$5M in Q1 2026.

• Operating cash outflow has remained persistently negative, ranging from -$3M to -$10M across all eight quarters with no improvement trend.

⚠ Equity has declined three straight quarters from $37M to $30M; ongoing burn without revenue will exhaust capital within several quarters.

⚠ Zero revenue across all eight quarters signals the company remains entirely pre-commercial, making future capital raises likely and dilutive.

AI Insight: CGTX Ratio Trends

Data is too sparse for margin or leverage trends, but ROE improved sharply from -167.3% in Q4 2024 to -39.0% in Q4 2025 before re-widening to -61.1% in Q1 2026.

• ROE improved from -167.3% in Q4 2024 to -39.0% in Q4 2025, suggesting reduced loss intensity through 2025.

• ROE deteriorated again to -61.1% in Q1 2026 from -39.0% in Q4 2025, reversing the recent improvement.

• ROA tracked ROE: improved from -82.0% in Q2 2024 to -27.6% in Q4 2025, then worsened to -50.6% in Q1 2026.

⚠ OpMargin, NPM, ROIC, and D/E are almost entirely absent — too little data to assess profitability or leverage trends.

⚠ Q1 2026 ROE re-widening to -61.1% after Q4 2025 low of -39.0% warrants monitoring for sustained loss acceleration.

Get alerted when CGTX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for COGNITION THERAPEUTICS INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CGTX

BIOS Capital Management, LP
$4.6M6,000,000 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.3M3,001,787 sh
DAVENPORT & Co LLC
$2.2M2,892,808 sh
RENAISSANCE TECHNOLOGIES LLC
$848.5K1,117,136 sh
Chescapmanager LLC
$757.2K997,029 sh
BlackRock, Inc.
$735.5K968,362 sh
GEODE CAPITAL MANAGEMENT, LLC
$699.2K920,208 sh
Hilton Capital Management, LLC
$416.9K548,950 sh
VANGUARD FIDUCIARY TRUST CO
$352.4K463,684 sh
Dauntless Investment Group, LLC
$327.3K431,000 sh

Fund	Value	Shares
BIOS Capital Management, LP	$4.6M	6,000,000
VANGUARD CAPITAL MANAGEMENT LLC	$2.3M	3,001,787
DAVENPORT & Co LLC	$2.2M	2,892,808
RENAISSANCE TECHNOLOGIES LLC	$848.5K	1,117,136
Chescapmanager LLC	$757.2K	997,029
BlackRock, Inc.	$735.5K	968,362
GEODE CAPITAL MANAGEMENT, LLC	$699.2K	920,208
Hilton Capital Management, LLC	$416.9K	548,950
VANGUARD FIDUCIARY TRUST CO	$352.4K	463,684
Dauntless Investment Group, LLC	$327.3K	431,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CGTX on your watchlist

Track score changes the day COGNITION THERAPEUTICS INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CGTX a good stock to buy?

13F Pro's AI-powered analysis of COGNITION THERAPEUTICS INC (CGTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CGTX are available on the CGTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CGTX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CGTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of COGNITION THERAPEUTICS INC's investment landscape.